Below is a list of the companies that made news in the healthcare sector on Monday, November 09, 2009.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the "Investors” section of the company’s website at www.alnylam.com.
Antares Pharma, Inc. (NYSE Amex: AIS) today reported financial and operating results for the third quarter ended September 30, 2009.
Biogen Idec Inc. (NASDAQ:BIIB) announced today that its presentation at the 2009 Annual Credit Suisse Healthcare Conference will be webcast live via the internet , on Friday, November 13, 2009 at 8:30 a.m. MST, 6:30 a.m. EST.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced its third quarter 2009 financial results.
CEL-SCI Corporation (NYSE:CVM) announced today that Dr. Kenneth S. Rosenthal, Professor of Immunology and Microbiology of Northeastern Ohio Universities College of Medicine and Pharmacy, reported on work conducted in collaboration with scientists at the Cleveland Clinic and CEL-SCI on CEL-SCI's LEAPS vaccine technology.
Clinical Data, Inc. (NASDAQ:CLDA) announced the Company’s operational and financial results for its second fiscal quarter ended September 30, 2009.
Compugen Ltd. (NASDAQ:CGEN) announced the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes the most common form of diabetes.
Commonwealth Biotechnologies, Inc. (NASDAQ:CBTE) is pleased to announce it has completed the divestment of the assets (excluding land and buildings) of its bioanalytical and genetic testing business units, CBI Services and Fairfax Identity Laboratory (FIL) for a cash consideration and an ongoing lease commitment for 5 years.
EpiCept Corporation (Nasdaq:EPCT) announced Health Canada has accepted for review the Company’s New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission.
Global Health Ventures Inc. (OTC:GHLV), or the "Company" a Specialty Pharma is pleased to announce it has completed the prototype manufacturing of the drug "X-Excite" Global's male enhancement drug.
Hercules Technology Growth Capital, Inc. (NASDAQ:HTGC), the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, announced it has committed to provide Labcyte, Inc. (www.labcyte.com) $5.5 million in credit facilities.
Lannett Company, Inc. (NYSE:LCI) reported financial results for the fiscal 2010 first quarter ended September 30, 2009.
Mannatech, Incorporated (NASDAQ:MTEX), a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, announced today their newest product, PhytoBurst™ Nutritional Chews.
Mentor Capital, Inc.'s (OTC:MNTR) major investee, Quantum Immunologics, reported significant advances in its recent Quarterly Conference Call.
Monsanto Company (NYSE:MON) and Pfizer Inc (NYSE: PFE) announced they have entered into an agreement for Monsanto to acquire Pfizer's Chesterfield Village Research Center located in Chesterfield, Mo.
OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced OSI Management will present at the Lazard Healthcare Conference in New York, NY on Tuesday, November 17, 2009 at 8:55am (Eastern Time) and will provide an overview on the Company’s product portfolio and business developments.
Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has extended the expiration date and increased the purchase price of it previously announced "Modified Dutch Auction" tender offer, in which Par is offering to purchase, for cash, up to $65,000,000 aggregate principal amount, or up to approximately 82.7%, of its outstanding 2.875% Senior Subordinated Convertible Notes due 2010.
Repros Therapeutics (Nasdaq:RPRX) announced financial results for the third quarter ended September 30, 2009.
SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.
Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today announced its financial results for the three and nine months ended September 30, 2009 and filed its third quarter Form 10-Q today with the U.S. Securities and Exchange Commission (SEC).
Walgreens (NYSE:WAG)(NASDAQ:WAG), Monthly total increases 185 percent over year ago E-prescribing promotes goals of health care reform as it lowers cost and improves adherence to drug therapy Federal stimulus package further bolsters electronic prescribing.
Walgreens (NYSE:WAG)(NASDAQ:WAG), President and CEO Greg Wasson will present during the Morgan Stanley Global Consumer and Retail Conference in New York on Thursday, Nov. 19, 2009 at approximately 8:20 a.m. EST.
Yasheng Group (OTC:YHGG), announced an agreement between Yasheng Group's majority shareholder Yasheng Group BVI and Yasheng ECO Trade Corp wherein Yasheng Eco Trade was to acquire 75,000,000 shares of Yasheng Group has been terminated due to a clause in the agreement that either party could terminated if the acquisition was not concluded by the end of September 2009.
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites